IP Library Granted Patent US 10,160,809
Granted Patent B2
US 10,160,809 · App. 15/411,938 · Granted Dec 25, 2018

Anti-TEM1 antibodies and uses thereof

Inventors: Nathalie Scholler (Penn Valley, PA); Aizhi Zhao (Drexel Hill, PA); Donald Siegel (Lansdale, PA); George Coukos (Vaud, CH)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
C07K16/2851A61K47/6849A61K2039/505C07K2317/21C07K2317/622C07K2317/77C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,160,809
App. No.
15/411,938
Granted
Dec 25, 2018
Kind
B2
Abstract

The invention relates to Anti-TEM 1 antibodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.

Claims (5)

1. A method of diagnosing the presence of a tumor or a cancer growth in a subject, said method comprising sampling a tissue sample isolated from said subject with a composition comprising an antibody or antigen-binding fragment thereof, wherein said antibody or antigen-binding fragment is specific for both the mouse and human form of an endosialin tumor endothelial marker 1 (TEM1) and binds to an epitope sequence as set forth in SEQ ID NO: 40, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising a CDR1 sequence of residues 31 to 35 of SEQ ID NO: 43; a CDR2 sequence of residues 50 to 65 of SEQ ID NO: 43; and a CDR3 sequence of residues 98 to 102 of SEQ ID NO: 43, and wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising a CDR1 sequence of residues 23 to 36 of SEQ ID NO: 48; a CDR2 sequence of residues 52 to 62 of SEQ ID NO: 48; and a CDR3 sequence of residues 97 to 104 of SEQ ID NO: 48, whereby specific binding of said antibody or antigen-binding fragment to said tissue sample is indicative of the presence of a tumor or cancer growth in said subject.

2. The method of claim 1 , further comprising a secondary reagent that specifically binds to said antibody or antigen-binding fragment but does not antagonize binding of said antibody or antigen-binding fragment to its target.

3. The method of claim 1 , whereby said secondary reagent is a photoactivatable agent, a fluorophore, a radioisotope, a bioluminescent protein, a bioluminescent peptide, a fluorescent tag, a fluorescent protein, or a fluorescent peptide.

4. The method of claim 1 , whereby said sampling comprises the step of analyzing said sample using a chromogenic immunological assay.

5. The method of claim 4 , whereby said sampling comprises the step of analyzing said sample using microscopic imaging.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2018
From: SCHOLLER, NATHALIE; ZHAO, AIZHI; SIEGEL, DONALD; COUKOS, GEORGE
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 047478/0136 →
Continuity (3)
Division 13508925
Provisional Application 61260286 · Nov 11, 2009
Related Publication 20170281793A1 · Oct 5, 2017